Paragon Care Limited · ASX:PGC
Paragon Care — Macquarie Emerging Leaders Conference (November 2021)
15 slides from Paragon Care's conference presentation, Nov 17, 2021
Slide 1: Paragon Care Limited Macquarie Emerging Leaders Conference
1 PARAGON CARE LIMITED (ASX: PGC) MACQUARIE EMERGING LEADERS CONFERENCE 17 November 2021
Slide 2: Disclaimer
2 PARAGON CARE DISCLAIMER This presentation has been prepared by Paragon Care Limited (ACN 064 551 426) (Paragon) (ASX: PGC) is current at the date of the presentation, 17 November 2021. This presentation is for information purposes only and is not a prospectus, product disclosure statement or other
Slide 3: Leading reseller of medical equipment in AUS & NZ
PARAGON CARE 3 LEADING RESELLER OF MEDICAL EQUIPMENT IN AUS & NZ ON BEHALF OF OVER 100 GLOBAL MANUFACTURERS CORE EXPERTISE IN Sales & Marketing Regulatory Approvals Service & Maintenance Logistics Capabilities Consumables Paragon Care Limited (ASX:PGC) 3
Slide 4: Established relationships across healthcare
PARAGON CARE 4 ESTABLISHED RELATIONSHIPS ACROSS HEALTHCARE GLOBAL MANUFACTURERS KEY BRANDS KEY CUSTOMERS Paragon Care Limited (ASX:PGC) 4
Slide 5: Diversified product offering across four pillars
PARAGON CARE 5 DIVERSIFIED PRODUCT OFFERING ACROSS FOUR PILLARS DEVICES DIAGNOSTICS CAPITAL & SERVICE & CONSUMABLES TECHNOLOGY MANAGEMENT EYE CARE BLOOD BANK UROLOGY, CRITICAL CARE REPORTING ORTHOPAEDICS LABORATORY NEONATAL, RADIOLOGY MAINTENANCE 36% 11% 45% 8% FY21 rev FY21 rev FY21 rev FY21 rev Pa
Slide 6: FY21 results: key highlights
PARAGON CARE 6 FY21 RESULTS: KEY HIGHLIGHTS Revenue EBITDA NPAT $236m $26.5m $8.3m ↑ 2% on pcp ↑16% on pcp* Diversified revenue streams Improved margins and streamlined operations Represents EPS of 2.45cps in product and geography *Normalised EBITDA OPCF Net Debt DPS $27.5m $69.1m 1.0cps ↑ 419% on p
Slide 7: FY22: Organic growth initiatives
PARAGON CARE 7 FY22: ORGANIC GROWTH INITIATIVES • We have a strong growth pipeline with 15 of the largest opportunities across the Group having the potential to increase sales by up to $100M in a 3 - 5 year time frame. • H2 FY22 gradual rebound from NSW, VIC & NZ lockdowns, specifically increased el
Slide 8: Creating a leading medical distribution business across Asia Pacific
PARAGON CARE 8 CREATING A LEADING MEDICAL DISTRIBUTION BUSINESS ACROSS ASIA PACIFIC SUMMARY OF MERGER • Paragon Care and Quantum are highly INDICATIVE TIMETABLE complementary medical distribution businesses • Under the Proposal, Paragon Care Ltd (ASX:PGC) Event Date will acquire 100% of the shares o
Slide 9: Strategic rationale for merger
9 STRATEGIC RATIONALE FOR MERGER Cross-Sell • Cross-sell the combined product portfolio into the high growth Asia Pacific markets Growth in Asia Pacific • Enhance growth opportunities in Asia, particularly for Immulab, in Paragon Care’s diagnostics pillar • Attract new suppliers through a larger dis
Slide 10: Established relationships across healthcare
10 ESTABLISHED RELATIONSHIPS ACROSS HEALTHCARE GLOBAL MANUFACTURERS LEADING BRANDS ASIA PACIFIC CUSTOMERS 10
Slide 11: A five pillar structure
11 A FIVE PILLAR STRUCTURE DEVICES DIAGNOSTICS CAPITAL & SERVICE & QUANTUM HEALTH CONSUMABLES TECHNOLOGY GROUP EYE CARE BLOOD BANK UROLOGY, CRITICAL CARE MANAGEMENT MEDICAL IMAGING, ORTHOPAEDICS LABORATORY NEONATAL, RADIOLOGY REPORTING & EQUIPMENT & SERVICES MAINTENANCE 30% 9% 36% 6% 19% FY21 Rev *
Slide 12: Consolidated FY21 metrics (pre-synergies)
12 CONSOLIDATED FY21 METRICS (Pre-Synergies) FY21 FY21 FY21 Consolidated Consolidated Consolidated Revenue1 EBITDA1 NPBT1 $291m $37m $21m Countries FY21 Gearing Australia Consolidated New Zealand Net Debt/EBITDA2 Ratio2 Korea < 2x 24% Thailand Philippines China Vietnam Notes: (1) Proforma numbers ar
Slide 13: Significant market opportunity for merged entity
13 SIGNIFICANT MARKET OPPORTUNITY FOR MERGED ENTITY A RISE IN SURGICAL PROCEDURES … INCREASED EXPENDITURE ON MEDICAL DEVICES.. A rise in surgical GROWING NUMBER OF SURGICAL PROCEDURES AUSTRALIAN MEDICAL DEVICES MARKET IS procedures is IN PUBLIC & PRIVATE HOSPITALS SIGNFICIANT AND GROWING increasing
Slide 14: Corporate overview post transaction
14 CORPORATE OVERVIEW POST TRANSACTION Major Shareholders (as at 3 Pro Forma Nov 2021)4 PGC QTM Combined Group Number of shares (m)2 351.40 1,128.31 625.58 Board, Management & 29.1% Market capitalisation (m) $101.2 $79.0 $180.2 Vendors Pre Merger Market Capitalisation (%) 56% 44% 100% China Pioneer
Slide 15: Thank you
15 Shane Tanner Chairman P: 1 300 369 559 E: [email protected] Stephen Munday Chief Financial Officer P: 1 300 369 559 E: [email protected] THANK YOU Paragon Care Limited (ASX:PGC) 15
Paragon Care — Macquarie Emerging Leaders Conference (November 2021) on 6ix